September 18, 2019
Phase I Study Results Show First-in-class NBTXR3 Could Present as a Valuable Option for Patients With Hepatocellular Carcinoma or Liver Metastasis
Nanobiotix’s radioenhancer NBTXR3 study showed encouraging results for Hepatocellular Carcinoma (HCC) patients, which are significant as they increase the scope of patients NBTXR3 may treat beyond Soft Tissue Sarcoma and Head and Neck cancer.